<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01101347</url>
  </required_header>
  <id_info>
    <org_study_id>SP-03</org_study_id>
    <nct_id>NCT01101347</nct_id>
  </id_info>
  <brief_title>A Feasibility Study of the Surpass Aneurysm-Embolization System in Intracranial Arteries</brief_title>
  <official_title>A Feasibility Study of the Surpass Aneurysm-Embolization System in Intracranial Arteries</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Surpass Medical Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Surpass Medical Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate safety and performance of the Surpass&#xD;
      Aneurysm-Embolization System.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Product received Approval for Commercial Distribution&#xD;
  </why_stopped>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Aneurysm</condition>
  <arm_group>
    <arm_group_label>Aneurysm-Embolization System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Aneurysm-Embolization System</intervention_name>
    <arm_group_label>Aneurysm-Embolization System</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject understands the nature of the procedure and provides written informed consent.&#xD;
&#xD;
          -  Subject is willing to return to the investigational site for the thirty day and six&#xD;
             month follow-up evaluations.&#xD;
&#xD;
          -  Age 18 years to 80 years.&#xD;
&#xD;
          -  Subject with a non-ruptured saccular, or fusiform intracranial aneurysm arising from a&#xD;
             parent vessel with a diameter of &gt; 2mm and &lt; 6mm.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Enrollment in another trial&#xD;
&#xD;
          -  Allergy or contraindication to aspirin, clopidogrel, heparin, local or general&#xD;
             anesthesia&#xD;
&#xD;
          -  History of life threatening allergy to contrast dye.&#xD;
&#xD;
          -  Major surgery within previous 30 days or planned in the next 90 days after enrollment&#xD;
             date.&#xD;
&#xD;
          -  Severe neurological deficit that renders the patient incapable of living independently&#xD;
&#xD;
          -  Dementia or psychiatric problem that prevents the patient from completing required&#xD;
             follow up&#xD;
&#xD;
          -  Co-morbid conditions that may limit survival to less than one year&#xD;
&#xD;
          -  Subject with anatomy not appropriate for endovascular treatment due to severe&#xD;
             intracranial vessel tortuosity or stenosis, or intracranial vasospasm not responsive&#xD;
             to medical therapy.&#xD;
&#xD;
          -  Subject with an intracranial mass (tumor (except meningioma), abscess, or other&#xD;
             infection), or is undergoing radiation therapy for carcinoma or sarcoma of the head or&#xD;
             neck region.&#xD;
&#xD;
          -  Subject has a history of bleeding diathesis or coagulopathy, international normalized&#xD;
             ratio (INR) greater than 1.5, or will refuse blood transfusions.&#xD;
&#xD;
          -  Subject has a serum creatinine level greater than 2.0 mg/dL (within 7 days of&#xD;
             procedure) which the investigator determines restricts the use of contrast agents.&#xD;
&#xD;
          -  Subject has a previously implanted intracranial stent associated with the symptomatic&#xD;
             distribution within the past 12 weeks prior to enrollment date&#xD;
&#xD;
          -  Stenting, angioplasty, or endarterectomy of an extracranial (carotid or vertebral&#xD;
             artery) or intracranial artery within 30 days prior to enrollment date&#xD;
&#xD;
          -  Subject has a previously implanted carotid stent associated with the symptomatic&#xD;
             distribution within the past 12 weeks prior to enrollment date&#xD;
&#xD;
          -  Subject has uncontrolled atrial fibrillation or known cardiac disorders likely to be&#xD;
             associated with cardioembolic symptoms.&#xD;
&#xD;
          -  Subject had a subarachnoid hemorrhage within 12 weeks prior to the enrollment date.&#xD;
&#xD;
          -  Subject with resistance to ASA and/or Clopidogrel.&#xD;
&#xD;
          -  Subject with two or more aneurysms in associated distribution - unless the device is&#xD;
             used to treat both aneurysms.&#xD;
&#xD;
          -  Subject has a non-treated arteriovenous malformation (AVM) in the territory of the&#xD;
             target aneurysm.&#xD;
&#xD;
          -  Target aneurysm is expected to require more than one device.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vipul Gupta, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medanta, Medcity</affiliation>
  </overall_official>
  <removed_countries>
    <country>India</country>
  </removed_countries>
  <verification_date>November 2010</verification_date>
  <study_first_submitted>April 8, 2010</study_first_submitted>
  <study_first_submitted_qc>April 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 9, 2010</study_first_posted>
  <last_update_submitted>November 26, 2010</last_update_submitted>
  <last_update_submitted_qc>November 26, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 30, 2010</last_update_posted>
  <responsible_party>
    <name_title>Marc Litzenberg</name_title>
    <organization>Surpass Medical, Ltd</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aneurysm</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

